ARCHIVES

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Study Finds Gene Expression Test Predicts Stage I or II Recurrence

August 30, 2013

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

July 31, 2009

Presidents’ FY93 Budget Holds NCI To $2 Billion, Gives NIH 5% Increase; Coalition ‘Disapionted’

February 7, 1992

Two Breast Cancer Treatments Show Similar Benefit In Trial

December 30, 2005

NCI-Approved Clinical Trials

June 24, 2005

DeCosse: Colorectal Screening Could Save 6,000 Lives Per Year

November 29, 1991